Production (Stage)
Pharming Group N.V.
PHAR
$11.86
$0.64775.78%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | 34.57% | 28.21% | 19.33% | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | 34.57% | 28.21% | 19.33% | |
| Cost of Revenue | -- | 72.97% | 77.02% | 44.23% | |
| Gross Profit | -- | 30.81% | 23.81% | 17.01% | |
| SG&A Expenses | -- | 19.56% | 31.44% | 37.52% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | 69.82% | 78.71% | 81.50% | |
| Total Operating Expenses | -- | 26.20% | 37.92% | 38.61% | |
| Operating Income | -- | 17.31% | -141.99% | -1,757.33% | |
| Income Before Tax | -- | 30.19% | -102.78% | -180.04% | |
| Income Tax Expenses | -- | 63.14% | 69.92% | -209.66% | |
| Earnings from Continuing Operations | -- | 18.84% | -440.48% | -177.14% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | 18.84% | -440.48% | -177.14% | |
| EBIT | -- | 17.31% | -141.99% | -1,757.33% | |
| EBITDA | -- | 44.20% | -405.43% | -363.87% | |
| EPS Basic | -- | 23.31% | -435.48% | -179.43% | |
| Normalized Basic EPS | -- | 60.72% | -80.66% | -80.66% | |
| EPS Diluted | -- | 27.40% | -108.54% | -208.23% | |
| Normalized Diluted EPS | -- | 60.72% | -70.31% | -70.31% | |
| Average Basic Shares Outstanding | -- | 4.93% | 6.49% | 3.95% | |
| Average Diluted Shares Outstanding | -- | 2.94% | -0.43% | -2.69% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |